Last reviewed · How we verify
AC VAX — Competitive Intelligence Brief
phase 2
Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
AC VAX (AC VAX) — Astellas Pharma Inc. AC VAX is a vaccine that stimulates the body's immune system to produce antibodies against a specific antigen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AC VAX TARGET | AC VAX | Astellas Pharma Inc | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). AC VAX — Competitive Intelligence Brief. https://druglandscape.com/ci/ac-vax. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab